Send to:

Choose Destination
See comment in PubMed Commons below
AIDS Res Hum Retroviruses. 2012 Apr;28(4):400-4. doi: 10.1089/AID.2011.0240. Epub 2011 Sep 27.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Author information

  • 1MHRP:HJF, Rockville, Maryland 20850, USA.


Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Mary Ann Liebert, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk